Anaplastic Astrocytoma Clinical Trial
Official title:
NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide
Background: The optimal treatment of anaplastic gliomas is controversial. Standard of care
in most centers is still radiotherapy. This phase III study compared the efficacy and safety
of radiotherapy vs chemotherapy in patients (pts) with newly-diagnosed, supratentorial
gliomas of WHO grade III.
Methods: Pts were randomized 2:1:1 between June 1999 and February 2005 in 34 German centers
to receive (i) a 6-week course of radiotherapy (1,8-2 Gy fractions, total dose 54-60 Gy) or
(ii) four 6-week cycles of CCNU at 110 mg mg/m2 on day 1, vincristine at 2 mg on days 8 and
29 and procarbazine at 60 mg/m2 on days 8-21 or eight 4-week cycles of 200 mg/m2
temozolomide on days 1-5. Treatment was stopped prematurely at disease progression or
occurrence of unacceptable toxicity. At this time or at disease progression, treatment in
the radiotherapy group was continued with one of the chemotherapies (1:1 randomization) and
with radiotherapy in both chemotherapy groups. The primary endpoint was
time-to-treatment-failure (TTF) defined as progression after radiotherapy and one
chemotherapy in either sequence, or any time before if further therapy could not be
employed. Assuming a 50% improvement in TTF of starting with chemotherapy, 318 pts were to
be enrolled to provide 80% power to achieve statistical significance at a one-sided level of
0.05.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT01765088 -
A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
|
Phase 3 | |
| Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01171469 -
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
|
Phase 1 | |
| Terminated |
NCT01227434 -
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
| Not yet recruiting |
NCT06333899 -
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
|
Early Phase 1 | |
| Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
| Active, not recruiting |
NCT01204684 -
Dendritic Cell Vaccine for Patients With Brain Tumors
|
Phase 2 | |
| Recruiting |
NCT03370926 -
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
|
N/A | |
| Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
| Completed |
NCT00390299 -
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
| Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01269853 -
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
|
Phase 1/Phase 2 | |
| Completed |
NCT00612651 -
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
|
Phase 1 | |
| Terminated |
NCT03332355 -
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
|
Phase 1 | |
| Completed |
NCT03043391 -
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
|
Phase 1 | |
| Active, not recruiting |
NCT03581292 -
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
|
Phase 2 | |
| Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 |